Welcome to LookChem.com Sign In|Join Free

CAS

  • or

372-75-8

Post Buying Request

372-75-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

372-75-8 Usage

Chemical Properties

White powder

Originator

StaminO2,ErgoPharm

Uses

Different sources of media describe the Uses of 372-75-8 differently. You can refer to the following data:
1. L-Citrulline, is used as an essential intermediate in the biosynthesis of nitric oxide from L-arginine . It is also used as a nutritional drink and biochemical reagent.
2. An amino acid, L-Citrulline can be used in the treatment of asthenia and as an essential intermediate in the biosynthesis of nitric oxide.
3. An essential intermediate in the biosynthesis of nitric oxide.

Manufacturing Process

Citrulline is obtained as a result of a reaction of L-arginine hydrochloride with sodium hydroxide, copper oxide and hydrogen sulfide. In practice it is usually used as malate salt

Therapeutic Function

Stimulant, Detoxicant

Biochem/physiol Actions

L-Citrulline, when orally administered is found to ameliorate the condition of sickle cell disease in humans. L-citrulline can be a replacement for L-arginine administration in case of defective NO synthetase. L-Citrulline supplementation is found to fulfill the purpose of NO-dependent signaling.

Purification Methods

Likely impurities are arginine and ornithine. Crystallise S-citrulline from water by adding 5 volumes of EtOH. Also crystallise it from water by addition of MeOH. [Ellenbogen J Am Chem Soc 74 5198 1952, Greenstein & Winitz The Chemistry of the Amino Acids J. Wiley, Vol 3 pp 2491-2494 1961, Beilstein 4 IV 2647.]

Check Digit Verification of cas no

The CAS Registry Mumber 372-75-8 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,7 and 2 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 372-75:
(5*3)+(4*7)+(3*2)+(2*7)+(1*5)=68
68 % 10 = 8
So 372-75-8 is a valid CAS Registry Number.
InChI:InChI=1/C6H13N3O3/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)/t4-/m0/s1

372-75-8 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (C0372)  L-Citrulline  >98.0%(T)

  • 372-75-8

  • 25g

  • 690.00CNY

  • Detail
  • TCI America

  • (C0372)  L-Citrulline  >98.0%(T)

  • 372-75-8

  • 250g

  • 3,750.00CNY

  • Detail
  • Alfa Aesar

  • (A13316)  L-Citrulline, 98%   

  • 372-75-8

  • 10g

  • 402.0CNY

  • Detail
  • Alfa Aesar

  • (A13316)  L-Citrulline, 98%   

  • 372-75-8

  • 50g

  • 1714.0CNY

  • Detail
  • Sigma

  • (C7629)  L-Citrulline  ≥98% (TLC)

  • 372-75-8

  • C7629-10MG

  • 242.19CNY

  • Detail
  • Sigma

  • (C7629)  L-Citrulline  ≥98% (TLC)

  • 372-75-8

  • C7629-1G

  • 386.10CNY

  • Detail
  • Sigma

  • (C7629)  L-Citrulline  ≥98% (TLC)

  • 372-75-8

  • C7629-5G

  • 473.85CNY

  • Detail
  • Sigma

  • (C7629)  L-Citrulline  ≥98% (TLC)

  • 372-75-8

  • C7629-25G

  • 1,382.94CNY

  • Detail
  • Sigma

  • (C7629)  L-Citrulline  ≥98% (TLC)

  • 372-75-8

  • C7629-100G

  • 4,215.51CNY

  • Detail
  • Sigma

  • (C7629)  L-Citrulline  ≥98% (TLC)

  • 372-75-8

  • C7629-500G

  • 16,953.30CNY

  • Detail
  • Sigma

  • (C7629)  L-Citrulline  ≥98% (TLC)

  • 372-75-8

  • C7629-1KG

  • 25,330.50CNY

  • Detail

372-75-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name L-citrulline

1.2 Other means of identification

Product number -
Other names (2S)-2-amino-5-(carbamoylamino)pentanoic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:372-75-8 SDS

372-75-8Synthetic route

L-arginine
74-79-3

L-arginine

Citrulline
372-75-8

Citrulline

Conditions
ConditionsYield
for 46 - 120h; Product distribution / selectivity; Enzymatic reaction;91%
With dihydrogen peroxide; K[Ru(Hedta)Cl]*2H2O71%
durch Einwirkung von Faeulnisbakterien;
L-ornithine
70-26-8

L-ornithine

Citrulline
372-75-8

Citrulline

Conditions
ConditionsYield
With carbamoyl phosphate
L-carglumic acid
1188-38-1

L-carglumic acid

Citrulline
372-75-8

Citrulline

Conditions
ConditionsYield
Biosynthese;
L-arginine hydrochloride
1119-34-2

L-arginine hydrochloride

Citrulline
372-75-8

Citrulline

Conditions
ConditionsYield
With dipotassium hydrogenphosphate; phosphoric acid; water at 25 - 37℃; Thermodynamic data; ΔH; aginine deiminase (EC 3.5.3.6) from Pseudomonas putida; var. pH and ionic strength;
L-ornithine-monohydrochloride

L-ornithine-monohydrochloride

Citrulline
372-75-8

Citrulline

Conditions
ConditionsYield
With copper (II) carbonate hydroxide; water at 100℃; Durch Erhitzen des erhaeltlichen Komplexsalzes mit Harnstoff in wss. Loesung auf 100grad und Zerlegung des gebildeten Kupfer(II)-Komplexsalzes des L-Citrullins mit H2S in Wasser;
Nω-allyl-L-arginine
139461-37-3

Nω-allyl-L-arginine

A

Citrulline
372-75-8

Citrulline

B

acrolein
107-02-8

acrolein

Conditions
ConditionsYield
With NADPH; calcium chloride; calmodulin; neuronal nitric oxide synthase at 20℃; pH=7.5; Enzyme kinetics; Oxidation; Enzymatic reaction;
Nω-allyl-Nω-hydroxy-L-arginine

Nω-allyl-Nω-hydroxy-L-arginine

A

Citrulline
372-75-8

Citrulline

B

acrolein
107-02-8

acrolein

Conditions
ConditionsYield
With NADPH; calcium chloride; calmodulin; neuronal nitric oxide synthase at 20℃; pH=7.5; Enzyme kinetics; Oxidation; Enzymatic reaction;
L-NOHA
53054-07-2

L-NOHA

Citrulline
372-75-8

Citrulline

Conditions
ConditionsYield
With mammalian nitric oxide synthase; oxygen Enzyme kinetics;
Nω-tert-butoxy-L-arginine

Nω-tert-butoxy-L-arginine

Citrulline
372-75-8

Citrulline

Conditions
ConditionsYield
With mammalian nitric oxide synthase; NADPH; diothiothreitol; tetrahydrobiopterin In various solvent(s) at 30℃; for 0.0333333h; Enzyme kinetics;
Nω-O-(3-methyl-2-butenyl)hydroxy-L-arginine

Nω-O-(3-methyl-2-butenyl)hydroxy-L-arginine

Citrulline
372-75-8

Citrulline

Conditions
ConditionsYield
With mammalian nitric oxide synthase; NADPH; diothiothreitol; tetrahydrobiopterin In various solvent(s) at 30℃; for 0.0333333h; Enzyme kinetics;
N-hydroxy-L-arginine

N-hydroxy-L-arginine

Citrulline
372-75-8

Citrulline

Conditions
ConditionsYield
With dihydrogen peroxide; Cl8TPPFe(III)Cl In various solvent(s) at 20℃;
Nω-hydroxy-L-arginine

Nω-hydroxy-L-arginine

Citrulline
372-75-8

Citrulline

Conditions
ConditionsYield
With full-length inducible nitric oxide synthase; (6R)-5,6,7,8-tetrahydro-L-biopterin; oxygen at 37℃; pH=7.4; Kinetics; aq. buffer;
With 1,4-dithio-D,L-threitol; neuronal NO synthase; NADPH; FAD; 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid; (6-R,S)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride; Flavin mononucleotide; superoxide dismutase; catalase; calmodulin at 25℃; Enzymatic reaction;
With recombinant murine inducible nitric oxide synthase-oxy substituted with mesohaem; (1'R,2'S,6R)-2-amino-6-(1',2'-dihydroxypropyl)-5,6,7,8-tetrahydropterin-4(3H)-one-dihydrochloride In aq. phosphate buffer Kinetics; Reagent/catalyst;
L-N-gamma-Aminoarginine

L-N-gamma-Aminoarginine

Citrulline
372-75-8

Citrulline

Conditions
ConditionsYield
With α-ketoglutaric acid; recombinant Giardia lamblia arginine deiminase; water; NADH at 25℃; Kinetics; Reagent/catalyst; Time; pH-value; aq. buffer;
L-ornithine hydrochloride
3184-13-2

L-ornithine hydrochloride

urea
57-13-6

urea

Citrulline
372-75-8

Citrulline

Conditions
ConditionsYield
Stage #1: L-ornithine hydrochloride With sodium hydrogencarbonate In water at 20℃;
Stage #2: With copper(ll) sulfate pentahydrate In water at 100℃;
Stage #3: urea Further stages;
Nω-hydroxy-L-arginine

Nω-hydroxy-L-arginine

A

Citrulline
372-75-8

Citrulline

B

nitrogen(II) oxide
10102-43-9

nitrogen(II) oxide

Conditions
ConditionsYield
With nitric oxide synthase; NADH at 25℃; Catalytic behavior; Kinetics; Enzymatic reaction;
L-arginine
74-79-3

L-arginine

A

Citrulline
372-75-8

Citrulline

B

nitrogen(II) oxide
10102-43-9

nitrogen(II) oxide

Conditions
ConditionsYield
With inducible NO synthase at 20℃; Enzymatic reaction;
With dihydrogen peroxide; C48H28ClFeN4O8 In aq. phosphate buffer for 0.416667h; pH=7.4; Kinetics; Green chemistry;
L-citrulline copper complex

L-citrulline copper complex

Citrulline
372-75-8

Citrulline

Conditions
ConditionsYield
With sodium sulfide In water Reagent/catalyst; Large scale;

372-75-8Relevant articles and documents

Dissecting structural and electronic effects in inducible nitric oxide synthase

Hannibal, Luciana,Page, Richard C.,Haque, Mohammad Mahfuzul,Bolisetty, Karthik,Yu, Zhihao,Misra, Saurav,Stuehr, Dennis J.

, p. 153 - 165 (2015)

Nitric oxide synthases (NOSs) are haem-thiolate enzymes that catalyse the conversion of L-arginine (L-Arg) into NO and citrulline. Inducible NOS (iNOS) is responsible for delivery of NO in response to stressors during inflammation. The catalytic performance of iNOS is proposed to rely mainly on the haem midpoint potential and the ability of the substrate L-Arg to provide a hydrogen bond for oxygen activation (O-O scission). We present a study of native iNOS compared with iNOS-mesohaem, and investigate the formation of a low-spin ferric haem-aquo or -hydroxo species (P) in iNOS mutant W188H substituted with mesohaem. iNOS-mesohaem and W188H-mesohaem were stable and dimeric, and presented substrate-binding affinities comparable to those of their native counterparts. Single turnover reactions catalysed by iNOSoxy with L-Arg (first reaction step) or N-hydroxy-L-arginine (second reaction step) showed that mesohaem substitution triggered higher rates of FeIIO2 conversion and altered other key kinetic parameters. We elucidated the first crystal structure of a NOS substituted with mesohaem and found essentially identical features compared with the structure of iNOS carrying native haem. This facilitated the dissection of structural and electronic effects. Mesohaem substitution substantially reduced the build-up of species P in W188H iNOS during catalysis, thus increasing its proficiency towards NO synthesis. The marked structural similarities of iNOSoxy containing native haem or mesohaem indicate that the kinetic behaviour observed in mesohaem-substituted iNOS is most heavily influenced by electronic effects rather than structural alterations.

Neuronal nitric oxide synthase isoforms α and μ are closely related calpain-sensitive proteins

Laine, Romuald,Ortiz De Montellano, Paul R.

, p. 305 - 312 (1998)

The neuronal nitric oxide synthase isoform nNOSμ, which is expressed in striated muscle, differs from nNOSα, the major brain isoform, by the insertion of 34 amino acid residues between the calmodulin- and flavin- binding domains [J Biol Chem 271:11204-11208 (1996)]. We show here that recombinant, purified nNOSμ, despite the peptide insertion, has the same spectroscopic properties, L-arginine k(cat) and K(m) values, optimal pH, and calmodulin binding affinity constant as nNOSα. However, nNOSμ consumes NADPH and reduces cytochrome c at approximately half the rate of nNOSα. The rates of degradation of the two proteins by rat brain and muscle homogenates show that nNOSμ is degraded more slowly than nNOSα. The in vitro half- lives of nNOSα and nNOSμ are 12 and 50 min, respectively, and calpain is important for this degradation. These short in vitro half-lives suggest that the nNOS isoforms are susceptible to rapid degradation in vivo. The elevated (20-fold) levels of calpain in diseased muscle tissue in Duchenne muscular dystrophy, and the hydrolytic sensitivity of both nNOSμ and nNOSα to this enzyme, may contribute to the deficiency of nNOS activity in the diseased tissue.

Directed evolution of an antitumor drug (Arginine Deiminase PpADI) for Increased Activity at Physiological pH

Zhu, Leilei,Tee, Kang Lan,Roccatano, Danilo,Sonmez, Burcu,Ni, Ye,Sun, Zhi-Hao,Schwaneberg, Ulrich

, p. 691 - 697 (2010)

Arginine deiminase (ADI; EC 3.5.3.6) has been studied as a potential antitumor drug for the treatment of arginine-auxotrophic tumors, such as hepatocellular carcinomas (HCCs) and melanomas. Studies with human lymphatic leukemia cell lines confirmed that ADI is an antiangiogenic agent for treating leukemia. The main limitation of ADI from Pseudomonas plecoglossicida (PpADI) lies in its pH-dependent activity profile, its pH optimum is at 6.5. A pH shift from 6.5 to 7.5 results in an approximately 80% drop in activity. (The pH of human plasma is 7.35 to 7.45.) In order to shift the PpADI pH optimum, a directed-evolution protocol based on an adapted citrulline-screening protocol in microtiter-plate format was developed and validated. A proof of concept for ADI engineering resulted in a pH optimum of pH 7.0 and increased resistance under physiological and slightly alkaline conditions. At pH 7.4, variant M2 (K5T/ D44E/H404R) is four times faster than the wild-type PpADI and retains -50% of its activity relative to its pH optimum, compared to -10% in the case of the wild-type PpADI.

Mechanisms of catalysis and inhibition operative in the arginine deiminase from the human pathogen Giardia lamblia

Li, Zhimin,Kulakova, Liudmila,Li, Ling,Galkin, Andrey,Zhao, Zhiming,Nash, Theodore E.,Mariano, Patrick S.,Herzberg, Osnat,Dunaway-Mariano, Debra

, p. 149 - 161 (2009)

Giardia lamblia arginine deiminase (GlAD), the topic of this paper, belongs to the hydrolase branch of the guanidine-modifying enzyme superfamily, whose members employ Cys-mediated nucleophilic catalysis to promote deimination of l-arginine and its naturally occurring derivatives. G. lamblia is the causative agent in the human disease giardiasis. The results of RNAi/antisense RNA gene-silencing studies reported herein indicate that GlAD is essential for G. lamblia trophozoite survival and thus, a potential target for the development of therapeutic agents for the treatment of giardiasis. The homodimeric recombinant protein was prepared in Escherichia coli for in-depth biochemical characterization. The 2-domain GlAD monomer consists of a N-terminal domain that shares an active site structure (depicted by an in silico model) and kinetic properties (determined by steady-state and transient state kinetic analysis) with its bacterial AD counterparts, and a C-terminal domain of unknown fold and function. GlAD was found to be active over a wide pH range and to accept l-arginine, l-arginine ethyl ester, Nα-benzoyl-l-arginine, and Nω-amino-l-arginine as substrates but not agmatine, l-homoarginine, Nα-benzoyl-l-arginine ethyl ester or a variety of arginine-containing peptides. The intermediacy of a Cys424-alkylthiouronium ion covalent enzyme adduct was demonstrated and the rate constants for formation (k1 = 80 s-1) and hydrolysis (k2 = 35 s-1) of the intermediate were determined. The comparatively lower value of the steady-state rate constant (kcat = 2.6 s-1), suggests that a step following citrulline formation is rate-limiting. Inhibition of GlAD using Cys directed agents was briefly explored. S-Nitroso-l-homocysteine was shown to be an active site directed, irreversible inhibitor whereas Nω-cyano-l-arginine did not inhibit GlAD but instead proved to be an active site directed, irreversible inhibitor of the Bacillus cereus AD.

IMPROVED METHOD OF SYNTHESIS AND PURIFICATION OF CITRULLINE

-

Paragraph 00033-00034; 00037-00038, (2020/12/29)

This invention provides for synthesis of citrulline from a transition metal complex of ornithine using cyanate to derivatize the terminal amino group of ornithine. The invention also provides improved methods for purification of citrulline produced by reaction of cyanate with ornithine via the steps of reprecipitation of copper complex of citrulline, removal of the complexing metal by sulfide precipitation, activated carbon adsorption and antisolvent crystallization.

Enzyme-immobilized metal-organic framework nanosheets as tandem catalysts for the generation of nitric oxide

Gao, Feng,Lei, Jianping,Ling, Pinghua,Qian, Caihua

supporting information, p. 11176 - 11179 (2020/04/23)

An enzyme-immobilized metal-organic framework (MOF) nanosheet system was developed as a tandem catalyst, which converted glucose into gluconic acid and H2O2, and sequentially the latter could be used to catalyze the oxidation of l-arginine to generate nitric oxide in the presence of porphyrinic MOFs as artificial enzymes under physiological pH, showing great potential in cancer depleting glucose for starving-like/gas therapy.

Engineering nitric oxide synthase chimeras to function as NO dioxygenases

Wang, Zhi-Qiang,Haque, Mohammad Mahfuzul,Binder, Katherine,Sharma, Manisha,Wei, Chin-Chuan,Stuehr, Dennis J.

, p. 122 - 130 (2016/06/08)

Nitric oxide synthases (NOSs) catalyze a two-step oxidation of l-arginine to form nitric oxide (NO) and l-citrulline. NOS contains a N-terminal oxygenase domain (NOSoxy) that is the site of NO synthesis, and a C-terminal reductase domain (NOSred) that binds nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), and flavin mononucleotide (FMN) and provides electrons to the NOSoxy heme during catalysis. The three NOS isoforms in mammals inducible NOS (iNOS), neuronal NOS (nNOS), and endothelial NOS (eNOS) share high structural similarity but differ in NO release rates and catalytic properties due to differences in enzyme kinetic parameters. These parameters must be balanced for NOS enzymes to release NO, rather than consume it in a competing, inherent NO dioxygenase reaction. To improve understanding, we drew on a global catalytic model and previous findings to design three NOS chimeras that may predominantly function as NO dioxygenases: iNOSoxy/nNOSred (Wild type (WT) chimera), V346I iNOSoxy/nNOSred (V346I chimera) and iNOSoxy/S1412D nNOSred (S1412D chimera). The WT and S1412D chimeras had higher NO release than the parent iNOS, while the V346I chimera exhibited much lower NO release, consistent with expectations. Measurements indicated that a greater NO dioxygenase activity was achieved, particularly in the V346I chimera, which dioxygenated an estimated two to four NO per NO that it released, while the other chimeras had nearly equivalent NO dioxygenase and NO release activities. Computer simulations of the global catalytic model using the measured kinetic parameters produced results that mimicked the measured outcomes, and this provided further insights on the catalytic behaviors of the chimeras and basis of their increased NO dioxygenase activities.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 372-75-8